PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20493430-1	2010	OBJECTIVE: In a previous study involving 18 hypertensive patients with type 2 diabetes mellitus, we found that replacement of valsartan and candesartan by telmisartan significantly improved insulin sensitivity and significantly increased serum adiponectin levels in the patients.	candesartan	140-151	adiponectin, C1Q and collagen domain containing	Homo sapiens	244-255	
20505674-10	2010	The M value, visfatin and ADN increased with candesartan, whereas no significant variations were observed with olmesartan.	candesartan	45-56	adiponectin, C1Q and collagen domain containing	Homo sapiens	26-29	
19059660-8	2010	Ramipril and candesartan therapies improved FMD and increased adiponectin levels and insulin sensitivity to a greater extent than atenolol or thiazide therapies (P<0.001 and P<0.015 by ANOVA).	candesartan	13-24	adiponectin, C1Q and collagen domain containing	Homo sapiens	62-73	
17483542-4	2007	Ramipril, candesartan, or combination therapy reduced blood pressure, improved flow-mediated dilation, and increased plasma adiponectin levels when compared with baseline values.	candesartan	10-21	adiponectin, C1Q and collagen domain containing	Homo sapiens	124-135	
20823643-9	2010	CONCLUSION: Switching from candesartan to telmisartan in obese subjects increases serum adiponectin and improves both insulin resistance and oxidative stress, while these effects were not statistically apparent in the total patient population.	candesartan	27-38	adiponectin, C1Q and collagen domain containing	Homo sapiens	88-99	
17483542-7	2007	There were correlations between percent changes in adiponectin levels and percent changes in insulin sensitivity (determined by QUICKI) (r = 0.319, P = 0.066) following ramipril therapy, percent changes in QUICKI (r = 0.374, P = 0.029) following combination therapy, and percent changes in QUICKI (r = 0.607, P < 0.001) following candesartan therapy.	candesartan	333-344	adiponectin, C1Q and collagen domain containing	Homo sapiens	51-62	
16940715-7	2006	Plasma adiponectin level increased from 12.5 to 18.8 microg/ml (p < 0.05) by candesartan and decreased again to 14.4 microg/ml (p < 0.05) after discontinuation.	candesartan	80-91	adiponectin, C1Q and collagen domain containing	Homo sapiens	7-18	
16443859-12	2006	Fenofibrate, combined therapy, and candesartan significantly increased plasma adiponectin levels and insulin sensitivity relative to baseline measurements.	candesartan	35-46	adiponectin, C1Q and collagen domain containing	Homo sapiens	78-89	
16246439-9	2006	Compared with placebo, candesartan therapy significantly lowered fasting insulin levels (P=0.011) and increased plasma levels of adiponectin by 15+/-4% (P=0.012) and increased QUICKI by 8+/-2% (P=0.007).	candesartan	23-34	adiponectin, C1Q and collagen domain containing	Homo sapiens	129-140	
16246439-11	2006	CONCLUSIONS: Candesartan therapy significantly reduced inflammation and increased adiponectin levels and improved insulin sensitivity in hypertensive patients.	candesartan	13-24	adiponectin, C1Q and collagen domain containing	Homo sapiens	82-93	
16940715-9	2006	CONCLUSION: Candesartan increases plasma adiponectin level in association with the reduction of oxidative stress in peritoneal dialysis patients.	candesartan	12-23	adiponectin, C1Q and collagen domain containing	Homo sapiens	41-52	
12796280-8	2003	Treatment with temocapril or candesartan significantly decreased blood pressure and increased M value and adiponectin concentrations but did not affect BMI and HDL cholesterol.	candesartan	29-40	adiponectin, C1Q and collagen domain containing	Homo sapiens	106-117	
25418492-9	2014	Treatment with high doses of the ARB, candesartan, is associated with significantly reduced LAR and marginally increased circulating adiponectin levels in hypertensive patients with multiple cardiovascular risk factors.	candesartan	38-49	adiponectin, C1Q and collagen domain containing	Homo sapiens	133-144